Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Type II Diabetes MellitusDyslipidemia
Interventions
DRUG

Pitavastatin

Pitavastatin 4 mg QD

DRUG

Atorvastatin

Atorvastatin 20 mg

Trial Locations (35)

Unknown

CCBR Aalborg, Aalborg

CCBR A/S, Ballerup Municipality

CCBR Vejle, Vejle

Gemeinschaftspraxis am Bahnhof, Berlin-Spandau

Pharmakologisches Studienzentum Chemnitz, Chemnitz

Internistische Diabetische Schwerpunktpraxis Dr., Frankfurt am Main

Internistische Gemeinschaftspraxis, Mainz

Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch

Bhagwan Mahaveer Jain Heart Centre, Bangalore

Sri Ramachandra Medical College Hospital, Chennai

Apollo Hospitals, Hyderabaad

CARE Group of Hospitals, Hyderabaad

PD Hinduja Hospital, Mumbai

Andromed Breda, Breda

Andromed Eindhoven, Eindhoven

Andromed Noord, Groningen

Andromed Leiden, Leiden

Andromed Nijmegen, Nijmegen

Andromed Rotterdam, Rotterdam

Andromed Oost, Velp

Andromed Zoetermeer, Zoetermeer

Podlaski Osrodek Kardiologii, Bialystok

NZOZ GCP Dobra Praktyka Lekaska, Gruziadz

NZOZ Terapia Optima, Katowice

NZOZ Centrum, Poradnia Kardiologiczna, Siedlce

Spec. Gab. Lek. Internistyczno-Kardiologicznly, Tarnów

Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego, Tychy

Instytut Zywnosci i Zywienia, Warsaw

Lecznica PROSEN SMO, Warsaw

Szpital Wolski,im. Dr A. Gostynskiej, Warsaw

NZOZ Esculap, Przychodnia Lekary Rodzinnych, Łosice

Synexus Reading Clinical Research Centre, Berkshire

Synexus Lancashire Clinical Research Centre, Lancashire

Synexus Merseyside Clinical Research Centre, Liverpool

Synexus Manchester Clinical Research Centre, Manchester

All Listed Sponsors
lead

Kowa Research Europe

INDUSTRY

NCT00309751 - Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia | Biotech Hunter | Biotech Hunter